2016/08/31 by Massimo Franchini, Pier Mannuccio Mannucci · 1 citation
Medicine · #Venous Thromboembolism Diagnosis and Management #Atrial Fibrillation Management and Outcomes #Blood Coagulation and Thrombosis Mechanisms #Medicine #Edoxaban #Rivaroxaban #Dabigatran #Apixaban #Deep vein #Direct thrombin inhibitor #Pulmonary embolism #Intensive care medicine #Narrative review #Thrombosis #Venous thromboembolism #Discovery and development of direct thrombin inhibitors #Anticoagulant #Venous thrombosis #Warfarin #Internal medicine #Atrial fibrillation #Thrombin
paper · pdf · doi:10.1183/16000617.0025-2016
openalex publication_date 2016/08/31 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/31
Venous thromboembolism (VTE), consisting of deep vein thrombosis and pulmonary embolism, is a major clinical concern associated with significant morbidity and mortality. The cornerstone of management of VTE is anticoagulation, and traditional anticoagulants include parenteral heparins and oral vitamin K antagonists. Recently, new oral anticoagulant drugs have been developed and licensed, including direct factor Xa inhibitors (e.g. rivaroxaban, apixaban and edoxaban) and thrombin inhibitors (e.g. dabigatran etexilate). This narrative review focusses on the characteristics of these direct anticoagulants and the main results of published clinical studies on their use in the prevention and treatment of VTE.